AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma

AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...